PP
UBX

PDT Partners’s Unity Biotechnology UBX Stock Holding History

PDT Partners’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,508
Closed -$225K – 1021
2021
Q3 		$225K Buy
7,508
+90
+1% +$3.17K 0.02% 663
2021
Q2 		$344K Buy
7,418
+395
+6% +$19K 0.02% 596
2021
Q1 		$421K Sell
7,023
-857
-11% -$58.4K 0.03% 537
2020
Q4 		$413K Buy
7,880
+3,390
+76% +$163K 0.03% 483
2020
Q3 		$155K Buy
4,490
+1,084
+32% +$68.6K 0.01% 653
2020
Q2 		$296K Buy
3,406
+619
+22% +$45.9K 0.02% 527
2020
Q1 		$162K Buy
2,787
+425
+18% +$26.8K 0.01% 581
2019
Q4 		$170K Buy
+2,362
New +$167K 0.01% 663

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

PDT Partners's UBX Position: Q4 2021 in Review

PDT Partners sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 7,508 shares — an estimated $225K sold.

PDT Partners first reported a position in UBX in Q4 2019 and held it in 8 quarters. The position peaked at $421K in Q1 2021. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

  • PDT Partners reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
  • PDT Partners sold 7,508 Unity Biotechnology shares in Q4 2021, an estimated $225K.
  • PDT Partners first reported a position in Unity Biotechnology in Q4 2019 and held it in 8 quarters.
  • PDT Partners's Unity Biotechnology position peaked at $421K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on PDT Partners's 13F filing for Q4 2021, filed 14 Feb 2022.